News
The price of crude oil dropped to $62.46 a barrel Monday morning, part of a downward trend that some analysts say could ...
Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...
Interestingly, Wall Street firms largely believe the former will playout in the long run. According to The Wall Street ...
The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...
Live Updates Live Coverage Has Ended Monday Wrap-up 4:11 pm The Vanguard S&P 500 ETF closed at 591.36 Monday, down 0.04%.
People who are prescribed Ozempic to treat type 2 diabetes, but whose insurance does not cover it, or who don’t have ...
Bloomberg on MSN14h
GoodRx Expands Access to Ozempic
GoodRx shares soar after announcing the company's partnership with Novo Nordisk to slash the cost of Ozempic. GoodRx CEO ...
Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...
Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...
Who benefits? The reduced price applies to self-paying patients—those without insurance, or whose insurance doesn’t cover ...
Novo Nordisk is working with GoodRx to offer a month’s supply of Ozempic for $499, or about half the list price, for self-paying patients. Ozempic, a drug approved for Type 2 diabetes, cardiovascular ...
Shares of GoodRx were spiking 35% on Monday. The announcement followed news from Novo Nordisk that the Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results